Management of Dry Mouth Toxicity Following ¹⁷⁷Lu-PSMA-617 Radioligand Therapy

Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with ¹⁷⁷Lu-PSMA-617. Although ¹⁷⁷Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of ¹⁷⁷Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.